A novel synthetic route for valrubicin, an anti-cancer drug, was proposed using a temperature-responsive lipase–Pluronic conjugate which gave an overall yield of 82% and a purity of 98% under mild conditions (50 °C, 6–8 h). The high activity, stability, selectivity and reusability of this new lipase catalyst hold great promise for practical applications.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: